Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (600866.SS)
Zhaoqing, CN
Established in 1964 and headquartered in Zhaoqing, China, Star Lake Bioscience Co., Inc. specializes in the production and global distribution of pharmaceutical ingredients, as well as food and animal feed additives. Its extensive product catalog includes guanosine, which serves as a crucial intermediate for both food and pharmaceutical applications. The company also manufactures L-proline, a vital intermediate for synthesizing captopril and enalapril, and a raw material used in amino acid transfusions. Another key offering is Adefovir dipivoxil tablets, formulated to combat Hepatitis B by inhibiting HBV DNA polymerase activity and disrupting the virus's DNA. Additionally, L-threonine is provided for its application in animal feed premixes, particularly for pigs and poultry. Star Lake Bioscience further supplies disodium 5'-ribonucleotide, utilized in the treatment of chronic hepatitis, muscular atrophy, and certain eye conditions. Similarly, disodium 5-inosinate addresses issues like leukopenia, thrombocytopenia, and both acute and chronic hepatitis. Inosine is another significant product, prescribed for various ailments including chronic hepatitis, heart disease, low white blood cell or platelet counts, and central choroidoretinitis. Furthermore, disodium 5'-guanylate finds application in food preservation, such as for canned meats, ham, and other salted meat products. The company's broad portfolio also features compounds such as ribavirin, adenosine, adenine, memantine hydrochloride, arginine, D-ribose, fructose syrup, L-valine, and L-lysine, among others. These diverse offerings are marketed under the proprietary brands Star Lake and Yue Bao.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.34% | -7.05% | -13.92% | -34.77% | -26.75% | -27.91% | -32.66% | -8.24% | +24.01% | -16.08% | +236.24% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-8.3% Q1'26: -7.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+3.5% Q1'26: -109.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+1.7% Q1'26: -27.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+8.1% ★ Q1'26: -0.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+8.8% ★ Q1'26: -0.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.51× Q1'26: -41.10× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
729.76M
est: 1.67B (-56.2%)
|
679.85M
est: 2.02B (-66.3%)
|
686.97M
est: 1.67B (-58.8%)
|
859.11M
est: 2.02B (-57.4%)
|
1.05B
est: 1.09B (-3.8%)
|
1.12B
est: 1.18B (-5.2%)
|
4.07B
est: 1.24B (+228.1%)
|
17.37B
est: 17.59B (-1.2%)
|
17.33B
est: 17.06B (+1.6%)
|
15.90B
est: 17.11B (-7.1%)
|
16.57B
16.57B – 16.57B
-3.1% YoY
|
17.64B
17.64B – 17.64B
+6.4% YoY
|
18.72B
18.72B – 18.72B
+6.2% YoY
|
| EBITDA |
-257.52M
est: 246.00M (-204.7%)
|
145.29M
est: 297.18M (-51.1%)
|
-39.41M
est: 246.00M (-116.0%)
|
137.54M
est: 297.18M (-53.7%)
|
259.06M
est: 160.90M (+61.0%)
|
258.62M
est: 173.73M (+48.9%)
|
469.73M
est: 183.03M (+156.6%)
|
1.90B
est: 2.24B (-15.4%)
|
2.18B
est: 2.17B (+0.5%)
|
2.12B
est: 2.18B (-2.5%)
|
2.11B
2.11B – 2.11B
-3.1% YoY
|
2.25B
2.25B – 2.25B
+6.4% YoY
|
2.38B
2.38B – 2.38B
+6.2% YoY
|
| EBIT |
-384.79M
est: 160.20M (-340.2%)
|
64.05M
est: 193.52M (-66.9%)
|
-118.83M
est: 160.20M (-174.2%)
|
58.24M
est: 193.52M (-69.9%)
|
171.72M
est: 104.78M (+63.9%)
|
170.70M
est: 113.14M (+50.9%)
|
366.28M
est: 119.19M (+207.3%)
|
1.05B
est: 1.43B (-26.7%)
|
1.35B
est: 1.38B (-2.5%)
|
1.29B
est: 1.39B (-7.4%)
|
1.34B
1.34B – 1.34B
-3.1% YoY
|
1.43B
1.43B – 1.43B
+6.4% YoY
|
1.52B
1.52B – 1.52B
+6.2% YoY
|
| Net Income |
-422.35M
est: 332.27M (-227.1%)
|
24.31M
est: 465.18M (-94.8%)
|
-158.27M
est: 332.27M (-147.6%)
|
42.28M
est: 465.18M (-90.9%)
|
149.55M
est: 382.11M (-60.9%)
|
148.71M
est: 415.34M (-64.2%)
|
152.14M
est: 448.57M (-66.1%)
|
677.95M
est: 954.00M (-28.9%)
|
943.15M
est: 946.99M (-0.4%)
|
978.89M
est: 1.36B (-28.1%)
|
1.06B
1.06B – 1.06B
-22.0% YoY
|
1.30B
1.30B – 1.30B
+21.9% YoY
|
1.50B
1.50B – 1.50B
+15.4% YoY
|
| SGA |
160.17M
est: 128.31M (+24.8%)
|
115.68M
est: 155.00M (-25.4%)
|
107.54M
est: 128.31M (-16.2%)
|
105.74M
est: 155.00M (-31.8%)
|
127.20M
est: 83.92M (+51.6%)
|
139.39M
est: 90.62M (+53.8%)
|
365.04M
est: 95.46M (+282.4%)
|
947.17M
est: 1.15B (-17.8%)
|
1.08B
est: 1.12B (-3.7%)
|
1.07B
est: 1.12B (-4.1%)
|
1.09B
1.09B – 1.09B
-3.1% YoY
|
1.15B
1.15B – 1.15B
+6.4% YoY
|
1.23B
1.23B – 1.23B
+6.2% YoY
|
| EPS |
-0.65
est: 0.20 (-425.0%)
|
0.04
est: 0.28 (-86.5%)
|
-0.25
est: 0.20 (-225.0%)
|
0.07
est: 0.28 (-76.6%)
|
0.20
est: 0.23 (-13.0%)
|
0.20
est: 0.25 (-20.0%)
|
0.19
est: 0.27 (-29.6%)
|
0.41
est: 0.57 (-28.6%)
|
0.57
est: 0.57 (+0.0%)
|
0.59
est: 0.82 (-28.0%)
|
0.64
0.64 – 0.64
-22.0% YoY
|
0.78
0.78 – 0.78
+21.9% YoY
|
0.90
0.90 – 0.90
+15.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-26 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-25 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 189.2K | 0.39% |
| 2 | WisdomTree Emerging Markets Equity Income UCITS ETF - Acc DEMR.L | 0.00% | 4.3K | 0.46% |
| 3 | WisdomTree Emerging Markets Equity Income UCITS ETF DEMD.L | 0.00% | 4.3K | 0.46% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 132.6K | 0.29% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 95.4K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jun Lai Chen | Financial Director | — | male |
| Kaijia Zhang | Board Secretary | — | male |
| Lijian Huang | Deputy General Manager | — | male |
| Xiaolin Yan | GM & Director | — | — |
| Xiaolong Yan | Deputy GM & Director | — | male |
| Yanjuan Liu | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600866.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
